Work Here?
Work Here?
Work Here?
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Total Funding
$114.5M
Headquarters
Redwood City, California
Founded
2010
Coherus BioSciences develops and sells biosimilars, which are highly similar versions of approved biologic medicines used to treat various diseases. These biosimilars are designed to be as effective and safe as the original products but are offered at a lower cost, making them more affordable for patients and healthcare systems. The company focuses on research, development, and commercialization of these products, ensuring they meet strict regulatory standards for quality and efficacy. Coherus aims to improve patient lives by expanding access to essential biologic treatments, thereby addressing the rising costs of healthcare. Their business model allows them to generate revenue through the sale of these cost-effective alternatives, giving them a competitive advantage in the biopharmaceutical market.
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$114.5M
Above
Industry Average
Funded Over
7 Rounds
Competitive base salary
Target bonus based on performance
stock options
Medical, dental, & vision coverage
PTO
401(k) plan
FSA
SK Capital Partners portfolio company Apotex has agreed to acquire the license to the Canadian rights to Toripalimab, an anti-PD-1 monoclonal antibody, from Coherus Biosciences.
Coherus Biosciences appoints Rita karachun to board.
Coherus BioSciences appoints Rita Karachun, CPA, CGMA to its Board of Directors.
Coherus BioSciences, Inc.REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus; Nasdaq: CHRS) today announced that the Cancer Research Institute (CRI) and its Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC) Drug Selection Committee (DSC) have selected LOQTORZI (toripalimab-tpzi), anti-PD-1 antibody, to explore in combination with ENB-003, a first-in-class small molecule inhibitor of endothelin B receptor (ETBR), for the treatment of drug-resistant cancers in the iPROC platform study. Endothelin B receptor is implicated in tumorigenesis and tumor immune suppression for several solid tumors, including melanoma, ovarian, and pancreatic cancers.“The iPROC DSC is pleased to have access to this next-generation PD-1 inhibitor and advance this combination supported by preclinical and clinical data in this study in ovarian cancer,” said John Stagg, Ph.D., Professor, Faculty of Pharmacy at the University of Montreal and Principal Investigator, Centre Hospitalier de l’Université de Montréal (CHUM) and its affiliated Cancer Institute of Montreal.Dr. Stagg continued, “The iPROC study DSC brings together a group of scientific experts within the CRI community to select promising combinations and rapidly advance them to clinical trials. Importantly, the DSC is not confined by a pipeline but looks to work with companies with drugs that have a strong data package. For this multiparty platform study to succeed, it requires science-driven, highly collaborative, and engaged companies
After a first-in-class FDA approval in nasopharyngeal carcinoma in October, Coherus launched Loqtorzi at the beginning of 2024.
Find jobs on Simplify and start your career today
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Total Funding
$114.5M
Headquarters
Redwood City, California
Founded
2010
Find jobs on Simplify and start your career today